<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00121615</url>
  </required_header>
  <id_info>
    <org_study_id>20040216</org_study_id>
    <nct_id>NCT00121615</nct_id>
  </id_info>
  <brief_title>Study of Etanercept in the Treatment of Psoriasis in Adult Subjects</brief_title>
  <official_title>An Open-Label, Long-Term Extension Study to Assess the Safety and Efficacy of Etanercept in the Treatment of Psoriasis in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The objective of the study is to describe the safety, tolerability, and efficacy of the
      long-term administration of etanercept in adults with psoriasis who have completed etanercept
      psoriasis study 20030115 or 20030117, in Canada, and are continuing in a long-term extension.
      Subjects from the 20030115 study will be followed for 24 months which began in Oct. 2004.
      Subjects in the 20030117 study will be followed for 12 months which began in mid 2005.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject incidence of serious adverse events, including serious infections, non-melanoma skin cancer, and all malignancies, and all adverse events.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Longitudinal changes from baseline for the Physician and Patient Global Assessments and DLQI</measure>
  </secondary_outcome>
  <enrollment>391</enrollment>
  <condition>Inflammation</condition>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Subjects who completed study 20030115 or 20030117 qualify to enroll
        into this study (provided that they meet all inclusion/exclusion criteria). -
        Heterosexually active men and women of child-bearing potential must agree to use a
        medically acceptable form of contraception throughout the study. - Subject or designee must
        have the ability to self-inject investigational product. - Subject must be capable of
        understanding and giving written voluntary informed consent. - Negative serum pregnancy
        test less than or equal to 14 days prior to the first dose of investigational product in
        all female subjects (except those surgically sterile or at least 5 years postmenopausal)
        Exclusion Criteria: - Active guttate, erythrodermic, or pustular psoriasis at the time of
        the baseline visit - Any adverse event or infection at the time of the baseline visit or at
        any time during the previous etanercept psoriasis study which, in the opinion of Amgen or
        the Investigator, would preclude participation in the study - Presence of a serious
        infection less than or equal to 30 days prior to the baseline visit - Evidence of skin
        conditions at the baseline visit (e.g., eczema) that would interfere with evaluations of
        the effect of investigational product on psoriasis - Previous receipt of anti-TNF agent(s)
        other than etanercept - Receipt of any investigational product(s), other than etanercept,
        less than or equal to 30 days prior to first dose of investigational product in this study
        - Receipt of anti-CD4 or diphtheria IL-2 fusion protein less than or equal to 24 weeks
        prior to first dose of investigational product in this study - Psoralen and ultraviolet A
        (PUVA) light therapy less than or equal to 14 days prior to first dose of investigational
        product in this study - Ultraviolet A (UVA) light therapy less than or equal to 14 days
        prior to first dose of investigational product in this study - Ultraviolet B (UVB) light
        therapy less than or equal to 14 days prior to first dose of investigational product in
        this study - Receipt of any other systemic psoriasis therapy or oral or parenteral
        corticosteroids less than or equal to 14 days prior to first dose of investigational
        product in this study - Pregnant or breast-feeding females - Significant concurrent medical
        conditions prior to enrollment, including: uncontrolled hypertension (defined as systolic
        blood pressure measurement of greater than 180 mm Hg or an untreated diastolic blood
        pressure of greater than 110 mm Hg); myocardial infarction less than or equal to 52 weeks
        prior to baseline visit; unstable angina pectoris; uncompensated congestive heart failure;
        severe pulmonary disease requiring hospitalization or supplemental oxygen therapy;
        diagnosis of multiple sclerosis or any other demyelinating disease; insulin-dependent
        diabetes mellitus; history of cancer (other than in-situ cervical cancer or resected
        cutaneous basal cell or squamous cell carcinoma) less than or equal to 5 years prior to
        administration of first dose of investigational product; open cutaneous ulcers; known human
        immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg) or hepatitis C virus
        (HCV) positive; any condition that might cause this study to be detrimental to the subject,
        in the judgment of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://www.enbrel.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>July 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <last_update_submitted>March 5, 2009</last_update_submitted>
  <last_update_submitted_qc>March 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Clinical Trials</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

